Radial Hemostasis Is Facilitated With a Potassium Ferrate Hemostatic Patch: The STAT2 Trial

JACC Cardiovasc Interv. 2022 Apr 25;15(8):810-819. doi: 10.1016/j.jcin.2021.12.030.

Abstract

Objectives: The aim of this trial was to test whether the potassium ferrate hemostatic patch (PFHP) as an adjunct to the TR Band (TRB) facilitated an early deflation protocol.

Background: Shorter TRB compression times may reduce the rate of radial artery occlusion (RAO) and reduce observation time after transradial access.

Methods: A total of 443 patients were randomized to the TRB or PFHP + TRB, with complete TRB deflation attempted 60 minutes postprocedure. The primary outcome was the time to successful full deflation of the TRB without bleeding, with secondary outcomes of time to discharge and complications including hematoma, RAO, or bleeding requiring intervention beyond TRB reinflation.

Results: Time to complete TRB deflation was 66 ± 14 minutes with the PFHP vs 113 ± 56 minutes for the TRB alone (P < 0.001). Minor rebleeding requiring TRB reinflation was much more frequent without the PFHP (0% vs 67.7%; P < 0.001) with 2.3 ± 1.3 additional reinflation and deflation attempts needed for hemostasis. Hematomas developed in 4.0% of the PFHP group and 6.8% of the TRB group (P = 0.20). RAO was rare (<1%), although 41% of patients received <5,000 U heparin. Among percutaneous coronary intervention patients, time to TRB deflation (68 ± 15 minutes vs 138 ± 62 minutes; P < 0.001) and composite complications (10.0% vs 24.2%; P = 0.04) were reduced with the PFHP.

Conclusions: Compared with the TRB alone, the PFHP facilitated early 60-minute TRB deflation following transradial catheterization, with a numeric reduction in vascular complications. RAO occurs rarely with early deflation regardless of heparin dose. (Comparing TR Band to StatSeal in Conjunction With TR Band II [StatSeal II]; NCT04046952).

Keywords: hemostatic agents; transradial catheterization; vascular complications.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Arterial Occlusive Diseases* / etiology
  • Cardiac Catheterization / adverse effects
  • Catheterization, Peripheral* / adverse effects
  • Hemostasis
  • Hemostatic Techniques
  • Hemostatics* / adverse effects
  • Heparin / adverse effects
  • Humans
  • Iron Compounds
  • Potassium Compounds
  • Radial Artery / diagnostic imaging
  • STAT2 Transcription Factor
  • Treatment Outcome

Substances

  • Hemostatics
  • Iron Compounds
  • Potassium Compounds
  • STAT2 Transcription Factor
  • STAT2 protein, human
  • potassium ferrate
  • Heparin

Associated data

  • ClinicalTrials.gov/NCT04046952